0001209191-16-135066.txt : 20160802
0001209191-16-135066.hdr.sgml : 20160802
20160802185103
ACCESSION NUMBER: 0001209191-16-135066
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160801
FILED AS OF DATE: 20160802
DATE AS OF CHANGE: 20160802
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kite Pharma, Inc.
CENTRAL INDEX KEY: 0001510580
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
BUSINESS ADDRESS:
STREET 1: 2225 COLORADO AVENUE
CITY: SANTA MONICA
STATE: CA
ZIP: 90404
BUSINESS PHONE: (310) 824-9999
MAIL ADDRESS:
STREET 1: 2225 COLORADO AVENUE
CITY: SANTA MONICA
STATE: CA
ZIP: 90404
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wiezorek Jeffrey
CENTRAL INDEX KEY: 0001610823
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36508
FILM NUMBER: 161801871
MAIL ADDRESS:
STREET 1: C/O KITE PHARMA, INC.
STREET 2: 2225 COLORADO AVENUE
CITY: SANTA MONICA
STATE: CA
ZIP: 90404
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2016-08-01
0
0001510580
Kite Pharma, Inc.
KITE
0001610823
Wiezorek Jeffrey
C/O KITE PHARMA, INC.
2225 COLORADO AVENUE
SANTA MONICA
CA
90404
0
1
0
0
SVP Clinical Development
Common Stock
2016-08-01
4
M
0
1500
6.89
A
16367
D
Common Stock
2016-08-01
4
S
0
891
56.66
D
15476
D
Common Stock
2016-08-01
4
S
0
609
57.24
D
14867
D
Employee Stock Option (Right to Buy)
6.89
2016-08-01
4
M
0
1500
0.00
D
2024-06-05
Common Stock
1500
80708
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 31, 2016.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.01 to $56.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.05 to $57.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
25% of the 175,000 shares subject to the stock option vested and became exercisable on May 5, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
/s/ David M. Tanen, Attorney-in-Fact
2016-08-02